DaVita Inc. (DVA)
NYSE: DVA · Real-Time Price · USD
147.02
+6.66 (4.74%)
At close: Mar 7, 2025, 4:00 PM
145.25
-1.77 (-1.20%)
After-hours: Mar 7, 2025, 5:21 PM EST
DaVita Revenue
In the year 2024, DaVita had annual revenue of $12.82B with 5.56% growth. DaVita had revenue of $3.29B in the quarter ending December 31, 2024, with 4.73% growth.
Revenue (ttm)
$12.82B
Revenue Growth
+5.56%
P/S Ratio
0.98
Revenue / Employee
$168,626
Employees
76,000
Market Cap
11.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12.82B | 675.40M | 5.56% |
| Dec 31, 2023 | 12.14B | 530.25M | 4.57% |
| Dec 31, 2022 | 11.61B | -8.90M | -0.08% |
| Dec 31, 2021 | 11.62B | 68.19M | 0.59% |
| Dec 31, 2020 | 11.55B | 162.13M | 1.42% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
DVA News
- 3 days ago - DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2025 - PRNewsWire
- 10 days ago - YMCA of the USA Deepens Collaboration with DaVita to Drive Kidney Health Initiatives in Seven Communities - GlobeNewsWire
- 18 days ago - Berkshire Hathaway sells another 750,000 DaVita shares - Reuters
- 23 days ago - DaVita's stock leads S&P 500 decliners after Berkshire pares stake. Its soft guidance isn't helping. - Market Watch
- 23 days ago - Warren Buffett's Berkshire Hathaway sells some DaVita; Shares fall on disappointing guidance - CNBC
- 24 days ago - DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Berkshire sells some DaVita shares, cuts stake to 45% - Reuters
- 24 days ago - DaVita forecasts 2025 profit below estimates, shares plummet - Reuters